Australian Researchers Develop AI Tool to Improve Cancer Treatment Monitoring
Researchers in Australia have developed a new digital tool designed to improve the detection and monitoring of side effects in cancer patients undergoing immunotherapy.
The system was created at the Peter MacCallum Cancer Centre and uses an advanced algorithm based on a “digital phenotype.” It analyzes electronic medical records to quickly and accurately identify patients who may develop immune-related colitis, a known inflammatory condition linked to immunotherapy treatment.
According to the research team, this approach significantly reduces the need for manual record reviews, allowing healthcare professionals to identify potential cases more efficiently and with greater consistency.
Lead researcher Dr. Jasmine Teng said the tool demonstrates how existing healthcare data can be used more effectively to support patient care and medical research. She noted that such technologies can help improve early detection and better management of treatment-related side effects.
Experts explain that immune-related colitis can affect a notable proportion of patients receiving immune checkpoint inhibitor therapy, making early identification important for timely intervention.
Researchers also believe the system could help identify patterns or biomarkers that predict which patients are more likely to develop side effects in the future. This could support more personalized treatment plans and improved patient safety.
Health specialists say the development highlights the increasing role of artificial intelligence and data-driven tools in modern healthcare, particularly in cancer treatment monitoring and clinical decision-making.
The research is expected to contribute to further studies aimed at improving outcomes for patients undergoing advanced cancer therapies.
